Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning.

Ahmadzadehfar H, Essler M.

Eur Urol. 2019 Mar 1. pii: S0302-2838(19)30175-7. doi: 10.1016/j.eururo.2019.02.028. [Epub ahead of print] No abstract available.

PMID:
30833140
2.

Diagnostic Challenges in Prostate Cancer and 68Ga-PSMA PET Imaging: A Game Changer?

Zaman MU, Fatima N, Zaman A, Sajid M, Zaman U, Zaman S.

Asian Pac J Cancer Prev. 2017 Oct 26;18(10):2625-2628.

3.

Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Chakravarty R, Siamof CM, Dash A, Cai W.

Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):247-267. eCollection 2018. Review.

4.

Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.

Afaq A, Bomanji J.

Br Med Bull. 2018 Dec 1;128(1):37-48. doi: 10.1093/bmb/ldy032.

PMID:
30272121
5.

68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study.

Lopci E, Saita A, Lazzeri M, Lughezzani G, Colombo P, Buffi NM, Hurle R, Marzo K, Peschechera R, Benetti A, Zandegiacomo S, Pasini L, Lista G, Cardone P, Castello A, Maffei D, Balzarini L, Chiti A, Guazzoni G, Casale P.

J Urol. 2018 Jul;200(1):95-103. doi: 10.1016/j.juro.2018.01.079. Epub 2018 Feb 1.

PMID:
29409824
6.

New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen.

Cimadamore A, Cheng M, Santoni M, Lopez-Beltran A, Battelli N, Massari F, Galosi AB, Scarpelli M, Montironi R.

Front Oncol. 2018 Dec 21;8:653. doi: 10.3389/fonc.2018.00653. eCollection 2018. Review.

7.

Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning.

Gupta SK, Watson T, Denham J, Shakespeare TP, Rutherford N, McLeod N, Picton K, Ainsworth P, Bonaventura T, Martin JM.

Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):701-709. doi: 10.1016/j.ijrobp.2017.06.2448. Epub 2017 Jun 27.

PMID:
29280465
8.

Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.

Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG.

Eur Urol. 2019 Feb 14. pii: S0302-2838(19)30095-8. doi: 10.1016/j.eururo.2019.01.049. [Epub ahead of print] Review.

PMID:
30773328
9.

Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.

Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL.

Semin Nucl Med. 2016 Sep;46(5):405-18. doi: 10.1053/j.semnuclmed.2016.04.004. Review.

PMID:
27553466
10.

Game changer: a new approach to strategic planning.

Hertz KT.

MGMA Connex. 2011 Oct;11(9):43-4. No abstract available.

PMID:
22375463
11.

New views into the prostate cancer genome.

Trotman L, Powers S.

Cancer Cell. 2010 Jul 13;18(1):1-2. doi: 10.1016/j.ccr.2010.06.011.

12.

Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer.

Rhee H, Thomas P, Shepherd B, Gustafson S, Vela I, Russell PJ, Nelson C, Chung E, Wood G, Malone G, Wood S, Heathcote P.

J Urol. 2016 Oct;196(4):1261-7. doi: 10.1016/j.juro.2016.02.3000. Epub 2016 May 21.

PMID:
27220897
13.

Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.

Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG.

J Nucl Med. 2018 Nov;59(11):1714-1721. doi: 10.2967/jnumed.118.209387. Epub 2018 Apr 13.

PMID:
29653978
14.

Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.

Dewes S, Schiller K, Sauter K, Eiber M, Maurer T, Schwaiger M, Gschwend JE, Combs SE, Habl G.

Radiat Oncol. 2016 May 26;11:73. doi: 10.1186/s13014-016-0646-2.

15.

New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.

Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M.

Eur Urol. 2016 Jul;70(1):161-175. doi: 10.1016/j.eururo.2016.01.029. Epub 2016 Feb 2. Review.

PMID:
26850970
16.

Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.

Tonttila PP, Lantto J, Pääkkö E, Piippo U, Kauppila S, Lammentausta E, Ohtonen P, Vaarala MH.

Eur Urol. 2016 Mar;69(3):419-25. doi: 10.1016/j.eururo.2015.05.024. Epub 2015 May 29.

PMID:
26033153
17.
18.

Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy.

Wüstemann T, Haberkorn U, Babich J, Mier W.

Med Res Rev. 2019 Jan;39(1):40-69. doi: 10.1002/med.21508. Epub 2018 May 17. Review.

PMID:
29771460
19.

Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells.

Guo Z, Huang H, Zeng L, Du T, Xu K, Lin T, Jiang C, Dong W, Cao Y, Chen J, Zhong W, Huang J.

Med Oncol. 2011 Sep;28(3):878-87. doi: 10.1007/s12032-010-9524-1.

PMID:
20390466
20.

Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.

Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, Schwarzenboeck SM, Kratowchil C, Herrmann K, Giesel FL.

J Nucl Med. 2017 Sep;58(Suppl 2):67S-76S. doi: 10.2967/jnumed.116.186767. Review.

Supplemental Content

Support Center